Mangoceuticals, Inc. (MGRX) Ratios
Mangoceuticals, Inc. Ratios
MGRX's free cash flow for Q2 2026 was $-260.51K. For the 2026 fiscal year, MGRX's free cash flow was increased by $0.00 and operating cash flow was $-260.51K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.74 | 0.05 | 3.88 | 2.67 | 0.57 |
| Quick Ratio | 1.74 | 0.05 | 3.79 | 2.67 | 0.57 |
| Cash Ratio | 1.67 | 0.04 | 3.50 | 2.62 | 0.57 |
| Solvency Ratio | -21.24 | -5.60 | -33.28 | -5.12 | -0.45 |
| Operating Cash Flow Ratio | -6.57 | -3.41 | -33.15 | -5.17 | -0.45 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -32.43 | 0.00 | -8.04 | -0.45 |
| Net Current Asset Value | $ 656.87K | $ -1.35M | $ 542.42K | $ 305.35K | $ -16.72K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.01 | 0.12 | 0.35 | 1.74 |
| Debt-to-Equity Ratio | 0.02 | 0.02 | 0.17 | 0.57 | -2.35 |
| Debt-to-Capital Ratio | 0.02 | 0.02 | 0.14 | 0.36 | 1.74 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.06 | 1.10 | 1.36 | 1.63 | -1.35 |
| Debt Service Coverage Ratio | -181.77 | -48.64 | 0.00 | -11.43 | -0.44 |
| Interest Coverage Ratio | -185.05 | -581.90 | 0.00 | -307.68 | -96.80 |
| Debt to Market Cap | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.12 | 0.12 | 0.31 | 0.04 |
| Net Debt to EBITDA | 0.06 | -0.02 | 0.08 | 0.17 | -0.95 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.91% | 61.70% | 58.99% | 54.26% | 0.00% |
| EBIT Margin | -4504.17% | -1411.65% | -1109.84% | -22279.70% | 0.00% |
| EBITDA Margin | -4126.07% | -1292.80% | -1106.44% | -22236.48% | 0.00% |
| Operating Profit Margin | -4200.46% | -1294.42% | -1260.28% | -22279.70% | 0.00% |
| Pretax Profit Margin | -4526.86% | -1413.77% | -1259.40% | -22352.11% | 0.00% |
| Net Profit Margin | -4526.86% | -1413.60% | -1259.40% | -22352.11% | 0.00% |
| Continuous Operations Profit Margin | -4526.86% | -1413.77% | -1259.40% | -22352.11% | 0.00% |
| Net Income Per EBT | 100.00% | 99.99% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 107.77% | 109.22% | 99.93% | 100.33% | 101.03% |
| Return on Assets (ROA) | -128.30% | -56.64% | -876.71% | -199.15% | -78.50% |
| Return on Equity (ROE) | -135.81% | -62.43% | -1189.08% | -325.40% | 105.87% |
| Return on Capital Employed (ROCE) | -126.03% | -57.17% | -1097.86% | -268.15% | 104.78% |
| Return on Invested Capital (ROIC) | -123.53% | -56.30% | -1020.43% | -205.98% | -77.69% |
| Return on Tangible Assets | -1111.60% | -6313.55% | -876.71% | -199.15% | -78.50% |
| Earnings Yield | -276.98% | -181.79% | -206.69% | -2.88% | -0.03% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.49 | 0.28 | 2.13 | 0.12 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 16.21 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.47 | 9.89 | 3.40 | 0.03 | 0.00 |
| Asset Turnover | 0.03 | 0.04 | 0.70 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | -1.32 | -1.66 | 1.40 | 0.04 | 0.00 |
| Cash Conversion Cycle | -739.61 | -1295.79 | -148.76 | -3005.96 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 22.51 | 0.00 | 0.00 |
| Days of Payables Outstanding | 739.61 | 1295.79 | 171.27 | 3005.96 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 22.51 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.58 | -2.46 | -6.52 | -1.17 | -0.02 |
| Free Cash Flow Per Share | -0.58 | -2.46 | -6.52 | -1.20 | -0.02 |
| Dividend Paid and CapEx Coverage Ratio | -1170051.00 | -6.06 | -1988.46 | -31.24 | 0.00 |
| Capital Expenditure Coverage Ratio | -1170051.00 | 0.00 | -1988.46 | -31.24 | 0.00 |
| Operating Cash Flow Coverage Ratio | -19.01 | -22.63 | -54.38 | -3.82 | -0.45 |
| Operating Cash Flow to Sales Ratio | -12.83 | -7.90 | -9.57 | -150.63 | 0.00 |
| Free Cash Flow Yield | -78.50% | -101.56% | -157.07% | -2.01% | -0.03% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.34 | -0.55 | -0.48 | -34.66 | -3381.73 |
| Price-to-Sales (P/S) Ratio | 16.34 | 7.78 | 6.09 | 7748.07 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.49 | 0.34 | 5.75 | 112.80 | -3580.14 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.27 | -0.98 | -0.64 | -49.84 | -3416.66 |
| Price-to-Operating Cash Flow Ratio | -1.27 | -0.98 | -0.64 | -51.44 | -3416.66 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.01 | -0.00 | -0.00 | 0.00 |
| Enterprise Value Multiple | -0.33 | -0.62 | -0.48 | -34.68 | -3417.62 |
| Enterprise Value | 6.27M | 4.95M | 3.85M | 68.93M | 59.88M |
| EV to EBITDA | -0.33 | -0.62 | -0.48 | -34.68 | -3417.62 |
| EV to Sales | 13.76 | 8.03 | 5.26 | 7711.15 | 0.00 |
| EV to Free Cash Flow | -1.07 | -1.02 | -0.55 | -49.60 | -3417.62 |
| EV to Operating Cash Flow | -1.07 | -1.02 | -0.55 | -51.19 | -3417.62 |
| Tangible Book Value Per Share | 0.10 | -0.65 | 0.72 | 0.53 | -0.02 |
| Shareholders’ Equity Per Share | 1.51 | 7.05 | 0.72 | 0.53 | -0.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.05 | 0.31 | 0.68 | 0.01 | 0.00 |
| Net Income Per Share | -2.05 | -4.40 | -8.58 | -1.73 | -0.02 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.00 | 1.13 | 1.00 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 36.67 | 12.82 | 4.54 | 183.87 | 0.00 |
| Stock-Based Compensation to Revenue | 2.56 | 0.40 | 0.85 | 26.19 | 0.00 |
| Income Quality | 0.28 | 0.56 | 0.76 | 0.67 | 0.99 |
Currency in USD